Carisma Therapeutics, Inc. CARM

NAS: CARM | ISIN: US14216R1014   2/05/2025
0,250 USD (+23,68%)
(+23,68%)   2/05/2025

31 maart 2025 · Carisma Therapeutics Provides Corporate Updates · Persbericht

10 september 2024 · Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases · Persbericht

3 september 2024 · Carisma Therapeutics to Present at Upcoming Conferences · Persbericht

8 augustus 2024 · Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights · Persbericht

6 augustus 2024 · Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 · Persbericht

6 augustus 2024 · Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board · Persbericht

1 juli 2024 · Carisma Therapeutics Announces Changes to its Board of Directors · Persbericht

27 juni 2024 · Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna · Persbericht

25 juni 2024 · Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors · Persbericht

25 juni 2024 · Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum · Persbericht

13 juni 2024 · Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders · Persbericht

30 mei 2024 · Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference · Persbericht

16 mei 2024 · Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte · Persbericht

9 mei 2024 · Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights · Persbericht

8 mei 2024 · Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024 · Persbericht

6 mei 2024 · Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference · Persbericht

2 mei 2024 · Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer · Persbericht

24 april 2024 · Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting · Persbericht

22 april 2024 · Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting · Persbericht

3 april 2024 · Carisma Therapeutics to Present at Upcoming Conferences · Persbericht

Mijn selecties